Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fluvastatin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR known ✓ | P04035 | 7/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 4/20 | 1.00 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 1.00 |
| ▸ | NR4A2 | P43354 | 2/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 2/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | RXRA | P19793 | 1/20 | 1.00 |
| ▸ | CCKAR | P32238 | 1/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 1.00 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.84 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.84 |
| ▸ | LMNA | P02545 | 1/20 | 0.84 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.84 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluvastatin SCHEMBL464787 | 1.00 | HMGCR (1.00) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL2847 | 1.00 | HMGCR (1.00) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL13501651 | 1.00 | HMGCR (1.00) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL556754 | 1.00 | HMGCR (1.00) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL628757 | 1.00 | HMGCR (1.00) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL6268460 | 1.00 | HMGCR (1.00) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL23468028 | 1.00 | HMGCR (1.00) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL2848 | 1.00 | HMGCR (1.00) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL2849 | 1.00 | HMGCR (1.00) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL4295454 | 1.00 | HMGCR (1.00) | HMGCRCYP2C9SIRT6NR4A2PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103126989-A | Application of preparing statins aerosol inhalant in airway inflammation disease | XIE YICHENG | 2013-06-05 | — | — | CN | claimed |
| CN-103126987-A | Fluvastatin quantification aerosol preparation and application of fluvastatin quantification aerosol in lung inflammatory disease | XIE YICHENG | 2013-06-05 | — | — | CN | claimed |
| EP-2076288-A2 | COMBINATION COMPRISING AN HMG-COA REDUCTASE INHIBITOR AND A SECOND NEUROGENIC AGENT FOR TREATING A NERVOUS SYSTEM DISORDER AND INCREASING NEUROGENESIS | Braincells, Inc. (US) | 2009-07-08 | — | — | EP | claimed |
| US-20080103105-A1 | HMG CoA REDUCTASE MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2008-05-01 | — | — | US | claimed |
| WO-2008036846-A2 | COMBINATION COMPRISING AN HMG-COA REDUCTASE INHIBITOR AND A SECOND NEUROGENIC AGENT FOR TREATING A NERVOUS SYSTEM DISORDER AND INCREASING NEUROGENESIS | BRAINCELLS, INC. (US) | 2008-03-27 | — | — | WO | claimed |
| EP-4659812-A1 | DETECTION METHODS AND COMBINATION THERAPIES OF CELLS WITH EXTRACELLULAR RAS EXPRESSION | Bumm, Thomas (DE) | 2025-12-10 | — | — | EP | disclosed |
| WO-2025119986-A1 | STATINS USEFUL IN THE TREATMENT OF SPLACHNIC VASCULAR DYSFUNCTIONS | HOSPITAL CLÍNIC DE BARCELONA (ES) | 2025-06-12 | — | — | WO | disclosed |
| EP-4566597-A1 | STATINS USEFUL IN THE TREATMENT OF SPLACHNIC VASCULAR DYSFUNCTIONS | Hospital Clínic de Barcelona (ES) | 2025-06-11 | — | — | EP | disclosed |
| CN-118845818-A | Ketohexokinase (KHK) iRNA compositions and methods of use thereof | 阿尔尼拉姆医药品有限公司 | 2024-10-29 | — | — | CN | disclosed |
| CN-118697894-A | Methods and compositions for treating proprotein convertase subtilisin KEXIN (PCSK 9) gene-related disorders | 阿尔尼拉姆医药品有限公司 | 2024-09-27 | — | — | CN | disclosed |
| CN-113057959-B | Ketohexokinase (KHK) iRNA compositions and methods of use thereof | 阿尔尼拉姆医药品有限公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-118079015-A | Methods and compositions for treating proprotein convertase subtilisin KEXIN (PCSK 9) gene-related disorders | 阿尔尼拉姆医药品有限公司 | 2024-05-28 | — | — | CN | disclosed |
| WO-2004047838-A2 | PHARMACEUTICAL COMPOSITION COMPRISING BETA-3-ADRENOCEPTOR AGONISTS AND ANTIMUSCARINIC AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-06-10 | — | — | WO | disclosed |
| US-20030032578-A1 | Antifungal and antiparasitic compounds | UNITED STATES GOVERNMENT | 2003-02-13 | — | — | US | disclosed |
| US-6462091-B1 | A TERTIARY AMINE SUBSTITUTED WITH A MONOCHLORINATED DIPHENYL-ETHER, A PHENYLPERFLUOROETHYL ETHER AND A HYDROXYLATED FLUORINATED ALKANE; SYNERGISTIC WITH MEVASTATIN, LOVASTATIN, SIMVASTATIN, PRAVASTATIN, FLUVASTATIN OR ATORVASTATIN | G.D. SEARLE & CO. | 2002-10-08 | — | — | US | disclosed |
| US-6403576-B1 | CHOLESTEROL SYNTHESIS INHIBITOR | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY | 2002-06-11 | — | — | US | disclosed |
| US-6264938-B1 | ADMINISTERING POLYDIALLYLAMINE AND HYDROXY-3-METHYLGLUTARYL/3-/, COENZYME A REDUCTASE | GELTEX PHARMACEUTICALS, INC. | 2001-07-24 | — | — | US | disclosed |
| CN-1255864-A | Combination of ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors | SEARLE & CO (US) | 2000-06-07 | — | — | CN | disclosed |
| EP-0971744-A2 | COMBINATION THERAPY EMPLOYING ILEAL BILE ACID TRANSPORT INHIBITING BENZOTHIEPINES AND HMG Co-A REDUCTASE INHIBITORS | G.D. SEARLE & CO. (US) | 2000-01-19 | — | — | EP | disclosed |
| WO-1998040375-A2 | COMBINATION OF ILEAL BILE ACID TRANSPORT INHIBITING BENZOTHIEPINES AND HMG Co-A REDUCTASE INHIBITORS | G.D. SEARLE & CO. (US) | 1998-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103105-A1 | HMG CoA REDUCTASE MEDIATED MODULATION OF NEUROGENESIS | HMGCR, DCX, SREBF1 | HMGCR 1/4885CYP2C9 4841/4885SIRT6 549/4885 |
| US-20030032578-A1 | Antifungal and antiparasitic compounds | PIGO, CAT, ERG28 | HMGCR 1005/4885CYP2C9 942/4885SIRT6 1955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.